As reported in a Safety Communication released by the U.S. Food and Drug Administration (FDA) on November 17, 2015, following the use of contrast media containing iodine, also called “contrast dye,” on an infant, that infant may suffer from underactive thyroid. While these cases are rare, the adverse effects of underactive thyroid in infancy may include slow growth, significant intellectual disability, and developmental delays.
CONTACT THE LAW FIRM OF ERIC H. WEINBERG FOR A FREE DRUG LAWSUIT CASE EVALUATION
Attorney Eric H. Weinberg has played a significant role in multiple mass tort litigations against corporate pharmaceutical defendants. He has represented plaintiffs in high profile drug lawsuits including Pradaxa, Vioxx, Baycol, and blood clotting products. For a free drug lawsuit evaluation, please call us toll free at 1-877-934-6274, or submit the easy-to-use Free Legal Case Evaluation Form. Our phones are answered 24/7.
To learn about more pharmaceutical drug lawsuits visit Accutane,Invokana, Benicar, Yaz, Zofran, Testosterone, and Pradaxa.
Details of Contrast Dye-Related Underactive Thyroid in Infants
In every reported case, the underactive thyroid had developed in infants who were either premature or had other serious underlying medical conditions.
The labels of all iodine-containing contrast dyes have been changed in consideration of these cases.
The FDA is requiring manufacturers of iodine-containing contrast dyes to conduct a study to investigate iodine contrast dye-related underactive thyroid in infants further.
Iodine-containing contrast dyes are used for X-rays and other medical imaging procedures in order to provide greater detail when necessary to help health care professionals diagnose potential problems. To see FDA Approved Marketed Iodinated Contrast Media Products visit the FDA Safety Communication regarding contrast dye-related underactive thyroid in infants.
